A Phase 3 interventional study of Maralixibat and Placebo in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 31 sites in 17 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.
33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.
Browse Cholestasis, progressive familial intrahepatic 1 studies →1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2019.
This study's enrollment of 93 is above the median of 60 across 11 interventional studies indexed under Cholestasis, progressive familial intrahepatic 1.
Median enrollment 84 across the 5 interventional studies, 250 across the 4 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 8 studies filed under Cholestasis, progressive familial intrahepatic 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).
This study was conducted at multiple sites in North America, Europe, Asia and South America.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of PFIC based on the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) orally twice daily for 26 weeks.
Drug: Maralixibat
Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
Other: Placebo
Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
Also known as: Formerly LUM001 and SHP625
Placebo matching to maralixibat orally twice daily for 26 weeks.
Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort
The primary efficacy endpoint is the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15-26, using 4-week average morning ItchRO(Obs) severity scores (Mixed Model Repeated Measures). The baseline average morning ItchRO(Obs) severity score is defined as the 4-week average morning ItchRO(Obs) severity score prior to the first dose of the study medication. ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.
Time frame: MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.
Mean Change in Total sBA Level in the Primary Cohort.
Mean change in total sBA level between baseline and average of Weeks 18, 22 and 26.
Time frame: Baseline and average of Weeks 18, 22 and 26
Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)
Mean change in the average morning ItchRO(Obs) severity score between baseline and Week 15 through Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.
Time frame: Between Baseline and Week 15 through Week 26
Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Mean change in total sBA level between baseline and average of Weeks 18, 22, and 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Time frame: Between Baseline and average of Weeks 18, 22 and 26
Proportion of ItchRO(Obs) Responders in the Primary Cohort
Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC2 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 or an average severity score of ≤1.0.
Time frame: Week 15 to Week 26 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26)
Proportion of sBA Responders in the Primary Cohort
Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC2, using the average value from Weeks 18, 22 and 26 values. The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), OR a ≤-75% average percent change from baseline.
Time frame: Average value from Weeks 18, 22 and 26
Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 OR an average severity score of ≤1.0.
Time frame: From Week 15 to Week 26
Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), or a ≤-75% average percent change from baseline.
Time frame: Week 18 to Week 26
A total of 93 participants were enrolled at 29 sites in 16 countries (Argentina, Austria, Belgium, Brazil, Canada, Colombia, France, Germany, Italy, Lebanon, Mexico, Poland, Singapore, Turkey, United Kingdom, and United States).
| Milestone | Maralixibat | Placebo |
|---|---|---|
| Started | 47 | 46 |
| Dosed 150 ug/kg bid | 47 | 0 |
| Dosed 300 ug/kg bid | 46 | 0 |
| Dosed 450 ug/kg bid | 45 | 0 |
| Dosed 600 ug/kg bid | 45 | 0 |
| Completed | 44 | 42 |
| Not completed | 3 | 4 |
The primary efficacy endpoint is the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15-26, using 4-week average morning ItchRO(Obs) severity scores (Mixed Model Repeated Measures). The baseline average morning ItchRO(Obs) severity score is defined as the 4-week average morning ItchRO(Obs) severity score prior to the first dose of the study medication. ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.
| Score on a scale | Primary Cohort Maralixibat | Primary Cohort Placebo |
|---|---|---|
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort | -1.718 (-2.272 to -1.163) | -0.628 (-1.136 to -0.121) |
Mean change in total sBA level between baseline and average of Weeks 18, 22 and 26.
| μmol/L | Primary Cohort Maralixibat | Primary Cohort Placebo |
|---|---|---|
| Mean Change in Total sBA Level in the Primary Cohort. | -175.536 (-256.716 to -94.356) | 11.187 (-58.073 to 80.446) |
Mean change in the average morning ItchRO(Obs) severity score between baseline and Week 15 through Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.
| score on a scale | PFIC Cohort Maralixibat | PFIC Cohort Placebo |
|---|---|---|
| Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6) | -1.811 (-2.178 to -1.444) | -0.610 (-1.000 to -0.221) |
Mean change in total sBA level between baseline and average of Weeks 18, 22, and 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
| μmol/L | PFIC Cohort Maralixibat | PFIC Cohort Placebo |
|---|---|---|
| Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | -157.489 (-200.276 to -114.703) | 2.913 (-42.320 to 48.146) |
Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC2 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 or an average severity score of ≤1.0.
| Number of responders | Primary Cohort Maralixibat | Primary Cohort Placebo |
|---|---|---|
| Proportion of ItchRO(Obs) Responders in the Primary Cohort | 8 | 4 |
Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC2, using the average value from Weeks 18, 22 and 26 values. The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), OR a ≤-75% average percent change from baseline.
| Number of responders | Primary Cohort Maralixibat | Primary Cohort Placebo |
|---|---|---|
| Proportion of sBA Responders in the Primary Cohort | 5 | 1 |
Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 OR an average severity score of ≤1.0.
| Number of responders | PFIC Cohort Maralixibat | PFIC Cohort Placebo |
|---|---|---|
| Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | 21 | 8 |
Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), or a ≤-75% average percent change from baseline.
| Number of responders | PFIC Cohort Maralixibat | PFIC Cohort Placebo |
|---|---|---|
| Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6) | 15 | 2 |
Collected over Baseline to end of treatment (EOT); where EOT can be up to 26 weeks if participant did not early terminate.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maralixibat | 0/47 (0%) | 5/47 (10.6%) | 47/47 (100%) |
| Placebo | 0/46 (0%) | 3/46 (6.5%) | 43/46 (93.5%) |
| Event | Maralixibat | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 2/47 | 0/46 |
| Accidental exposure to productInjury, poisoning and procedural complications | 0/47 | 1/46 |
| CoagulopathyBlood and lymphatic system disorders | 0/47 | 1/46 |
| Gastroenteritis viralInfections and infestations | 0/47 | 1/46 |
| SeizureNervous system disorders | 0/47 | 1/46 |
| Vitamin K deficiencyMetabolism and nutrition disorders | 0/47 | 1/46 |
| Blood bilirubin increasedInvestigations | 1/47 | 0/46 |
| CholestasisHepatobiliary disorders | 1/47 | 0/46 |
| ConstipationGastrointestinal disorders | 1/47 | 0/46 |
| Idiopathic pneumonia syndromeRespiratory, thoracic and mediastinal disorders | 1/47 | 0/46 |
| Event | Maralixibat | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 27/47 | 9/46 |
| PyrexiaGeneral disorders | 17/47 | 13/46 |
| Abdominal painGastrointestinal disorders | 10/47 | 3/46 |
| PruritusSkin and subcutaneous tissue disorders | 5/47 | 8/46 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 8/47 | 5/46 |
| Blood bilirubin increasedInvestigations | 7/47 | 4/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/47 | 5/46 |
| Upper respiratory tract infectionInfections and infestations | 3/47 | 6/46 |
| Alanine aminotransferase increasedInvestigations | 6/47 | 3/46 |
| InfluenzaInfections and infestations | 6/47 | 2/46 |
| Age, Categorical(Participants) | Maralixibat | Placebo | Total |
|---|---|---|---|
| All subjects — <=18 years | 47 | 46 | 93 |
| All subjects — Between 18 and 65 years | 0 | 0 | 0 |
| All subjects — >=65 years | 0 | 0 | 0 |
| Primary Cohort — <=18 years | 14 | 17 | 31 |
| Primary Cohort — Between 18 and 65 years | 0 | 0 | 0 |
| Primary Cohort — >=65 years | 0 | 0 | 0 |
| PFIC cohort — <=18 years | 33 | 31 | 64 |
| PFIC cohort — Between 18 and 65 years | 0 | 0 | 0 |
| PFIC cohort — >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Maralixibat | Placebo | Total |
|---|---|---|---|
| All subjects | 4.8 ± 4.15 | 4.7 ± 3.57 | 4.7 ± 3.85 |
| Primary Cohort | 6.3 ± 5.24 | 4.2 ± 3.56 | 5.1 ± 4.45 |
| PFIC Cohort | 4.9 ± 4.10 | 4.4 ± 3.61 | 4.6 ± 3.85 |
| Sex: Female, Male(Participants) | Maralixibat | Placebo | Total |
|---|---|---|---|
| All subjects — Female | 27 | 24 | 51 |
| All subjects — Male | 20 | 22 | 42 |
| Primary Cohort — Female | 7 | 11 | 18 |
| Primary Cohort — Male | 7 | 6 | 13 |
| PFIC Cohort — Female | 16 | 18 | 34 |
| PFIC Cohort — Male | 17 | 13 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Maralixibat | Placebo | Total |
|---|---|---|---|
| All subjects — Hispanic or Latino | 18 | 17 | 35 |
| All subjects — Not Hispanic or Latino | 28 | 27 | 55 |
| All subjects — Unknown or Not Reported | 1 | 2 | 3 |
| Primary Cohort — Hispanic or Latino | 9 | 7 | 16 |
| Primary Cohort — Not Hispanic or Latino | 5 | 9 | 14 |
| Primary Cohort — Unknown or Not Reported | 0 | 1 | 1 |
| PFIC Cohort — Hispanic or Latino | 16 | 13 | 29 |
| PFIC Cohort — Not Hispanic or Latino | 17 | 16 | 33 |
| PFIC Cohort — Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Maralixibat | Placebo | Total |
|---|---|---|---|
| All subjects — American Indian or Alaska Native | 3 | 4 | 7 |
| All subjects — Asian | 3 | 0 | 3 |
| All subjects — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| All subjects — Black or African American | 1 | 2 | 3 |
| All subjects — White | 36 | 34 | 70 |
| All subjects — More than one race | 3 | 4 | 7 |
| All subjects — Unknown or Not Reported | 1 | 2 | 3 |
| Primary Cohort — American Indian or Alaska Native | 3 | 3 | 6 |
| Primary Cohort — Asian | 0 | 0 | 0 |
| Primary Cohort — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Primary Cohort — Black or African American | 1 | 2 | 3 |
| Primary Cohort — White | 9 | 9 | 18 |
| Primary Cohort — More than one race | 1 | 2 | 3 |
| Primary Cohort — Unknown or Not Reported | 0 | 1 | 1 |
| PFIC Cohort — American Indian or Alaska Native | 3 | 4 | 7 |
| PFIC Cohort — Asian | 3 | 0 | 3 |
| PFIC Cohort — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| PFIC Cohort — Black or African American | 1 | 2 | 3 |
| PFIC Cohort — White | 24 | 19 | 43 |
| PFIC Cohort — More than one race | 2 | 4 | 6 |
| PFIC Cohort — Unknown or Not Reported | 0 | 2 | 2 |
| Region of Enrollment(participants) | Maralixibat | Placebo | Total |
|---|---|---|---|
| Argentina | 2 | 1 | 3 |
| Austria | 1 | 1 | 2 |
| Belgium | 3 | 0 | 3 |
| Brazil | 7 | 3 | 10 |
| Canada | 1 | 1 | 2 |
| Colombia | 2 | 4 | 6 |
| France | 1 | 2 | 3 |
| Germany | 1 | 1 | 2 |
| Italy | 2 | 4 | 6 |
| Lebanon | 6 | 8 | 14 |
| Mexico | 3 | 5 | 8 |
| Poland | 4 | 2 | 6 |
| Singapore | 2 | 0 | 2 |
| Turkey | 1 | 1 | 2 |
| United Kingdom | 2 | 0 | 2 |
| United States | 9 | 13 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Sep 2022, 37 months.
Results were first posted in Dec 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat
Cholestasis, progressive familial intrahepatic 1 →